The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma

PURPOSE OF REVIEW: Dual immune checkpoint inhibition with ipilimumab plus nivolumab is currently the most effective, but also by far the most toxic treatment for advanced melanoma. Therefore, other combination partners that also lead to high and long-lasting responses but cause fewer adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Albrecht, Lea Jessica, Livingstone, Elisabeth, Zimmer, Lisa, Schadendorf, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164023/
https://www.ncbi.nlm.nih.gov/pubmed/37004702
http://dx.doi.org/10.1007/s11912-023-01406-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164023/
https://www.ncbi.nlm.nih.gov/pubmed/37004702
http://dx.doi.org/10.1007/s11912-023-01406-4

Ejemplares similares